Trial Profile
A Double-blind, Randomized, 6-sequence, 3-period, Crossover Drug Drug Interaction Study to Evaluate the Pharmacokinetics of Wellbutrin SR and GSK189075 When Co-administered or Administered Alone in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jun 2023
Price :
$35
*
At a glance
- Drugs Bupropion (Primary) ; Remogliflozin etabonate (Primary)
- Indications Depressive disorders; Obesity; Seasonal affective disorder; Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 27 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Aug 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 21 Apr 2008 New trial record.